Jump Financial LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,717 shares of the biopharmaceutical company's stock after buying an additional 572 shares during the period. Jump Financial LLC's holdings in Alnylam Pharmaceuticals were worth $4,244,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares during the last quarter. AQR Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 60.9% during the fourth quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company's stock worth $191,391,000 after buying an additional 307,702 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter worth $69,292,000. Price T Rowe Associates Inc. MD increased its holdings in Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after buying an additional 185,783 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Alnylam Pharmaceuticals by 30,759.4% during the first quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company's stock worth $44,913,000 after buying an additional 165,793 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on ALNY. HC Wainwright boosted their target price on shares of Alnylam Pharmaceuticals from $500.00 to $570.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $405.33.
Check Out Our Latest Report on ALNY
Insider Buying and Selling
In other news, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the sale, the executive vice president owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $632,764.92. Following the completion of the sale, the executive vice president directly owned 22,719 shares of the company's stock, valued at approximately $10,297,841.13. The trade was a 5.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 108,531 shares of company stock valued at $41,087,238 in the last 90 days. 1.20% of the stock is currently owned by corporate insiders.
Alnylam Pharmaceuticals Price Performance
NASDAQ:ALNY opened at $443.64 on Tuesday. The firm's fifty day moving average price is $363.34 and its two-hundred day moving average price is $298.14. The company has a market cap of $58.15 billion, a P/E ratio of -179.61 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $469.81. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.
About Alnylam Pharmaceuticals
(
Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access